DIA: Driving Insights to Action
Science:Life Sciences
On July 1 2018, Dr. Joseph Scheeren (Senior Advisor, R&D, Bayer) became Chair of the DIA Board of Directors. “In this time of great change, it is great to be part of an organization like DIA, which wants to bring stakeholders together in order to discuss and foster the development of new products and new technologies,” he explains. “We have a unique opportunity not only to bring these stakeholders together but also to serve as a platform for information for our members and even beyond our members.”
Patient-Focused Drug Development: What Must We Still Do?
Interchangeable Biosimilars: A Global Perspective
Game Technology Opens New Path to Clinical Endpoints
Challenges and Opportunities for South Africa’s New Regulatory System
Clinical, Data, and Quantitative Science Now Converging
Realizing the Full Potential of CRISPR: Is the Hype Getting in the Way of Progress?
Tackling Ethical Questions in Clinical Research and Drug Development
WHO 2030 Framework for Efficient, Effective Regulation
AI: Opportunity for More Informed Drug Development Decisions
Clinical Training Critical in China’s Cancer Fight
Changing Research in China: From Generics to Innovators
Running Away from Addiction Has Caught Up with US
Has the Time for Big/Real World Data Finally Arrived?
Will AI Make Workers More (or Less) Valuable?
PvPI: Technology Meets Opportunity to Improve Safety
New EU CTR: One Application, One Portal, One Decision
US Generic Drug Policy: Less Cost, Same Impact
Multiple Pathways Complicate Opioid Pain Management
Breakthrough for Patients & Regulatory Science
DIA 2018 Co-Chair: Patient Activists Are “Our Best Friends”
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Stuff To Blow Your Mind
Speaking of Psychology